The Effectiveness of Ganciclovir Comparing with Combination Therapy of Oxytetracycline HCI and Polymyxin B Sulfate in Herpetic Epithelial Keratitis

Year 2019, Volume: 5 Issue: 1, 60 - 64, 01.01.2019

Oguz Guvenmez Asim Kayiklik

https://doi.org/10.5455/umj.20191024045517

Abstract

Introduction: Herpes simplex virus is a common keratitis agent. There are two different types of virus, type 1 and 2. Type 1 shows three main clinical pictures in cornea: epithelial herpetic keratitis, stromal keratitis, disciform keratitis. The aim of this study is to reduce the duration of herpetic keratitis treatment and eliminate the risk of complications. Material and Methods: Between January 2017 and January 2018, 29 patients with herpetic keratitis were included in the study. In the first group, the herpetic membrane was removed by a single shot on the herpetic lesion with the yag laser. Then, topically oxytetracycline hydrochloride+polymyxin B sulfate was applied. The second group was treated with topical antiviral therapy Ganciclovir . After treatment, daily follow-up of patients, vision, tonus, fundus diameters and recovery times were noted and the data were compared statistically. Results: In group I and group II, the age of the patients did not differ significantly p> 0.05 . In group I and group II, the gender distribution of the patients did not differ significantly p>0.05 . In Group I and Group II, the degree of vision did not differ significantly p>0.05 . In group I and group II, the examination findings were not significant p>0.05 . In group I and group II, recovery time was significantly different p

Keywords

Herpetic epithelial keratitis, ganciclovir, oxytetracycline HCl, polymyxin B sulfate

References

• 1. Darougar S, Wishart MS, Viswalingam ND. Epidemiological and clinical features of primary herpes simplex virus ocular infection. Br J Ophthalmol. 1985;69(1):2–6
• 2. Liesegang TJ, Melton LJ, Daly PJ, Ilstrup DM. Epidemiology of ocular herpes simplex: incidence in Rochester, Minn, 1950 through 1982. Arch Ophthalmol. 1989;107(8):1155–1159
• 3. Tang Q, Chen W, Hendricks RL. Proinflammatory functions of IL-2 in herpes simplex virus corneal infection. J Immunol. 1997;158(3):1275–1283
• 4. Tsatsos M, MacGregor C, Athanasiadis I, Moschos MM, Hossain P, Anderson D. Herpes simplex virus keratitis: an update of the pathogenesis and current treatment with oral and top- ical antiviral agents. Clin Exp Ophthalmol. 2016;44(9):824–837
• 5. White ML, Chodosh J. Herpes simplex virus keratitis; A Treatment Guideline. 2014. Massachusetts Eye and Ear Infirmary Department of Ophthalmology, Harvard Medical School. Reviewed and endorsed by the Ocular Microbiology and Immunology Group
• 6. Farooq AV, Shukla D. Herpes simplex epithelial and stromal keratitis: an epidemiologic update. Surv Ophthalmol. 2012;57(5):448–62
• 7. Miserocchi E, Modorati G, Galli L, Rama P. Efficacy of valacyclovir vs. acyclovir for the prevention of recurrent herpes simplex virus eye disease: A pilot study. Am J Ophthalmol. 2007;144(4):547–51
• 8. Chong DY, Johnson MW, Huynh TH, Hall EF, Comer GM, Fish DN. Vitreous penetration of orally administered famciclovir. Am J Ophthalmol. 2009;148(1):38–42
• 9. Roozbahani M, Hammersmith KM. Management of herpes simplex virus epithelial keratitis. Curr Opin Ophthalmol. 2018; 29(4): 360-364
• 10. Komoto S, Higaki S, Fukuda M, et al. Effects of antiviral medications on herpetic epithelial keratitis in mice. Jpn J Ophthalmol 2015; 59:194-200
• 11. Sozen E, Avunduk AM, Akyol N. Comparison of efficacy of oral valacyclovir and topical acyclovir in the treatment of herpes simplex keratitis: a randomized clinical trial. Chemo therapy 2006; 52:29-31
• 12. Loutsch JM, Sainz B Jr, Marquart ME, et al. Effect of famciclovir on herpes simplex virus type 1 corneal disease and establishment of latency in rabbits. Antimicrob Agents Chemother 2001; 45:2044-2053